klionmac.blogg.se - Human japanese intermediate trial

#Human japanese intermediate trial update#
#Human japanese intermediate trial driver#
#Human japanese intermediate trial trial#

Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation.

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine.

Positive Dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting.

New preclinical tolebrutinib data demonstrated superior brain penetration and potency.

Availability of the Q4 2021 Memorandum for modelling purposes.

Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria.

Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines.

Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board.

#Human japanese intermediate trial update#

Sanofi and Regeneron provide regulatory update on Libtayo® (cemiplimab-rwlc) in advanced cervical cancer.Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine.Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants.Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines.Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1.Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022.Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program.Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD.Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis.FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence.Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity.

Press Release: Availability of the Q1 2022 Memorandum for modelling purposes.Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets.

#Human japanese intermediate trial driver#

Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver.

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment.

Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis.

Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis.

#Human japanese intermediate trial trial#

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial.Sanofi recognized by S&P as one of the most sustainability-committed companies.Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris.Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates.Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma.Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency.Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer.